Predictors and Growth Consequences of Central Hypothyroidism in Pediatric Patients Receiving Recombinant Human Growth Hormone

Wong, Kara; Levitsky, Lynne L.; Misra, Madhusmita
May 2010
Journal of Pediatric Endocrinology & Metabolism;May2010, Vol. 23 Issue 5, p451
Academic Journal
The article offers information on a study which examined the prevalence, predictors and growth outcome of evolving hypothyroidism in children given with recombinant human growth hormone (rhGH) based on therapeutic indication. Indications for rhGH initiation include growth hormone deficiency (GHD), Prader-Willi syndrome and Turner syndrome, among others. A discussion on the research findings is detailed. It concludes that the development of central hypothyroidism is more prevalent in patients receiving rhGH for GHD than other indications.


Related Articles

  • "Anything you can do, I can do bigger?": the ethics and equity of growth hormone for small normal children. Gill, D. G. // Archives of Disease in Childhood;Mar2006, Vol. 91 Issue 3, p270 

    This paper argues against the use of growth hormone (GH) for small normal children (‘idiopathic’ short stature) with the following considerations: ethical (philosophical) grounds, cost-economic implications, and the rationale for treating normal physiological variation with a potent...

  • The Efficacy of Growth Hormone Therapy on Children with Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone. Essa, Kassim Rahi; Al-Jumaili, Ali Hasan; Ali Hasan, Waseem; Salih, Bushra Jaleel // Tikrit Medical Journal;Jun2010, Vol. 16 Issue 1, p184 

    The use of growth hormone (GH) in clinical endocrine practice is expanding and its role in the treatment of various clinical conditions is increasingly appreciated. Concurrently, concerns have been raised about the ethnical, economic, safety and efficacy of growth hormone and this study in this...

  • Growth hormone treatment in non-growth hormone-deficient children. Loche, Sandro; Carta, Luisanna; Ibba, Anastasia; Guzzetti, Chiara // Annals of Pediatric Endocrinology & Metabolism;2014, Vol. 19 Issue 1, p1 

    Until 1985 growth hormone (GH) was obtained from pituitary extracts, and was available in limited amounts only to treat severe growth hormone deficiency (GHD). With the availability of unlimited quantities of GH obtained from recombinant DNA technology, researchers started to explore new...

  • Growth hormone for short children without a hormone deficiency: Issues and practices. Lee, Joyce M.; Menon, Ram K. // Contemporary Pediatrics;Oct2005, Vol. 22 Issue 10, p46 

    This article discusses the indications for growth hormone (GH) in children who are not GH-deficient which have gained approval from the U.S. Food and Drug Administration (FDA) as of 2005. Children with chronic renal insufficiency, Turner syndrome, or Prader-Willi syndrome, children who are born...

  • Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome. l'Allemand, Dagmar; Eiholzer, Urs; Schlumpf, Michael; Steinert, Hans; Riesen, Walter; l'Allemand, D; Eiholzer, U; Schlumpf, M; Steinert, H; Riesen, W // European Journal of Pediatrics;2000, Vol. 159 Issue 11, p835 

    Unlabelled: Cardiovascular risk factors in Prader-Willi syndrome (PWS, OMIM 176270) may be independently caused by overweight or hypothalamic growth hormone (GH) deficiency. The present observational study in 23 children with PWS, aged 0.3-14.6 years, focuses on the specific...

  • GH Treatment.  // Current Medical Literature: Growth, Growth Hormone, & Metabolism;2008, Vol. 2 Issue 1, p23 

    The article presents abstracts of studies on growth hormone (GH) treatment including thyroid hormone levels in children with Prader-Willi syndrome before and during GH treatment, impact of five years of GH replacement therapy on cardiovascular risk factors in GH-deficient adults and GH treatment...

  • Prader--Willi syndrome.  // Current Medical Literature: Growth, Growth Hormone, & Metabolism;2008, Vol. 2 Issue 2, p57 

    The article presents information on studies about Prader-Willi syndrome (PWS). One study reveals that growth hormone treatment of adults with PWS and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment. Another study...

  • Central precocious puberty and growth hormone deficiency in a boy with Prader-Willi syndrome. Crinò, Antonino; Di Giorgio, Girolamo; Schiaffini, Riccardo; Fierabracci, Alessandra; Spera, Sabrina; Maggioni, Andrea; Gattinara, Guido Castelli; Crinò, Antonino // European Journal of Pediatrics;Dec2008, Vol. 167 Issue 12, p1455 

    In Prader-Willi syndrome (PWS) hypothalamic dysfunction is the cause of hormonal disturbances, such as growth hormone deficiency (GHD), hypogonadism, and delayed or incomplete puberty. Only a few cases of central precocious puberty (CPP) have been reported. We describe an 8.8-year-old PWS boy,...

  • A Stepwise Increase in Recombinant Human Growth Hormone Dosing During Puberty Achieves Improved Pubertal Growth: A National Cooperative Growth Study Report. Riddick, Linda; Alter, Craig; Davis, D. Aaron; Frane, James; Lippe, Barbara; Bakker, Bert // Journal of Pediatric Endocrinology & Metabolism;Jul2009, Vol. 22 Issue 7, p623 

    The article discusses a study of the near adult height (NAH) improvement of children variedly treated during puberty with increased doses of recombinant human growth hormone (rhGH). It is stated that in patients attaining NAH after three years, an increase of 3.6 centimeters (cm) in mean height...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics